For the quarter ending 2025-09-30, SLRX made $916,793 in revenue. -$873,467 in net income. Net profit margin of -95.27%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 61,826 | 116,383 | ||
| General and administrative | 833,304 | 849,182 | ||
| Total operating expenses | 895,130 | 965,565 | ||
| Loss before other income (expense) | -895,130 | -965,565 | ||
| Interest income, net | 21,663 | 7,740 | ||
| Loss from continuing operations | -873,467 | -957,825 | ||
| Net loss | -873,467 | -957,825 | ||
| Loss per common share, basic ( in dollar per share) | -1.81 | -0.45 | ||
| Loss per common share, diluted ( in dollar per share) | -1.81 | -0.45 | ||
| Weighted average number of common shares outstanding, basic (in shares) | 481,587 | 2,122,872 | ||
| Weighted average number of common shares outstanding, diluted (in shares) | 481,587 | 2,122,872 | ||
Salarius Pharmaceuticals, Inc. (SLRX)
Salarius Pharmaceuticals, Inc. (SLRX)